Compare DORM & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DORM | TLX |
|---|---|---|
| Founded | 1978 | 2015 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.9B |
| IPO Year | 1996 | 2024 |
| Metric | DORM | TLX |
|---|---|---|
| Price | $132.98 | $11.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | ★ $160.25 | $21.13 |
| AVG Volume (30 Days) | ★ 324.1K | 88.5K |
| Earning Date | 05-04-2026 | 08-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.14 | N/A |
| EPS | ★ 4.35 | N/A |
| Revenue | ★ $2,130,319,000.00 | N/A |
| Revenue This Year | $9.70 | N/A |
| Revenue Next Year | $4.92 | N/A |
| P/E Ratio | ★ $30.53 | $150.33 |
| Revenue Growth | ★ 6.03 | N/A |
| 52 Week Low | $98.45 | $6.28 |
| 52 Week High | $166.88 | $12.60 |
| Indicator | DORM | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 47.04 | 61.64 |
| Support Level | $131.69 | $10.01 |
| Resistance Level | $142.43 | $12.23 |
| Average True Range (ATR) | 5.93 | 0.19 |
| MACD | -0.72 | 0.14 |
| Stochastic Oscillator | 29.90 | 82.28 |
Dorman Products Inc is a supplier of original equipment parts for automobiles. It offers automotive and heavy-duty replacement parts, automotive hardware, brake parts, and fasteners for the automotive and heavy-duty aftermarket. The products are sold under the Dorman brand and its sub-brands OE Solutions, Help!, Conduct-Tite, Super ATV, etc., through aftermarket retailers, warehouse distributors, specialty markets, and salvage yards. The company operates through three business segments, which include Light Duty, Heavy Duty, and Specialty Vehicle. A majority of its revenue is generated from the Light Duty segment, which designs and markets replacement parts and fasteners mainly for passenger cars and light trucks. Geographically, it derives key revenue from the United States.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.